用于膀胱癌诊断和监测的尿液标志物
Urinary Markers for Bladder Cancer Diagnosis and Monitoring.
作者信息
Jeong Seung-Hwan, Ku Ja Hyeon
机构信息
Department of Urology, Seoul National University Hospital, Seoul, South Korea.
Department of Urology, Seoul National University College of Medicine, Seoul, South Korea.
出版信息
Front Cell Dev Biol. 2022 May 2;10:892067. doi: 10.3389/fcell.2022.892067. eCollection 2022.
Abstract
Hematuria is a typical symptom of bladder cancer which enables early detection of bladder cancer. However, reliable diagnostic tools for bladder cancer using urine samples or other non-invasive methods are lacking. Tremendous attempts have been tried and revealed fancy works to convey definitive diagnostic power using urine samples. In this paper, we reviewed urinary markers for bladder cancer and compared their efficacies.
摘要
血尿是膀胱癌的典型症状，有助于早期发现膀胱癌。然而，目前缺乏使用尿液样本或其他非侵入性方法诊断膀胱癌的可靠工具。人们已经进行了大量尝试，并取得了一些引人注目的成果，试图利用尿液样本实现明确的诊断能力。在本文中，我们综述了膀胱癌的尿液标志物，并比较了它们的诊断效能。
相似文献
1
Urinary Markers for Bladder Cancer Diagnosis and Monitoring.用于膀胱癌诊断和监测的尿液标志物
Front Cell Dev Biol. 2022 May 2;10:892067. doi: 10.3389/fcell.2022.892067. eCollection 2022.
2
Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?补体因子H相关蛋白（BTA-TRAK检测）和核基质蛋白（NMP22检测）的测量——膀胱癌诊断中的有用诊断工具？
Clin Chem Lab Med. 2003 Jan;41(1):104-10. doi: 10.1515/CCLM.2003.018.
3
Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.优化膀胱癌尿液标志物研究的试验设计：协作综述。
Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15.
4
Multiple Chromatographic Analysis of Urine in the Detection of Bladder Cancer.尿液的多重色谱分析在膀胱癌检测中的应用
Diagnostics (Basel). 2021 Sep 28;11(10):1793. doi: 10.3390/diagnostics11101793.
5
[Bladder cancer screening with urine-based tumour markers - occupational medical experience].[基于尿液肿瘤标志物的膀胱癌筛查——职业医学经验]
Aktuelle Urol. 2011 Mar;42(2):128-34. doi: 10.1055/s-0031-1271424. Epub 2011 Mar 24.
6
Republished: non-invasive urine based tests for the detection of bladder cancer.再版：基于尿液的非侵入性膀胱癌检测方法。
Postgrad Med J. 2013 Jun;89(1052):352-7. doi: 10.1136/postgradmedj-2012-200812rep.
7
Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation.利用 DNA 甲基化标志物检测尿液中的膀胱癌：一项技术和前瞻性临床前验证。
Clin Epigenetics. 2022 Feb 5;14(1):19. doi: 10.1186/s13148-022-01240-8.
8
Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma.NMP22和尿细胞学检查在血尿或有尿路上皮癌病史患者中的临床应用。
World J Urol. 2000 Dec;18(6):401-5. doi: 10.1007/s003450000124.
9
UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.尿液中的泛素结合酶E2C无细胞RNA能够区分膀胱癌和血尿。
Oncotarget. 2016 Sep 6;7(36):58193-58202. doi: 10.18632/oncotarget.11277.
10
Urinary fluorescence analysis in diagnosis of bladder cancer.尿荧光分析在膀胱癌诊断中的应用。
Neoplasma. 2018;65(2):234-241. doi: 10.4149/neo_2018_170610N420.
引用本文的文献
1
The current status of miRNA in urinary bladder cancer: A minireview and strength, weakness, opportunity, and threat analysis.miRNA在膀胱癌中的现状：一篇综述及优势、劣势、机遇与威胁分析
Indian J Urol. 2025 Apr-Jun;41(2):98-103. doi: 10.4103/iju.iju_442_24. Epub 2025 Apr 1.
2
Urinary extracellular vesicle N-glycomics identifies diagnostic glycosignatures for bladder cancer.尿液细胞外囊泡N-糖组学鉴定膀胱癌的诊断性糖基特征。
Nat Commun. 2025 Mar 7;16(1):2292. doi: 10.1038/s41467-025-57633-9.
3
Multi-cancer early detection tests: a strategy for improvement.多癌早期检测测试：一种改进策略。
BMJ Oncol. 2024 Jan 9;3(1):e000184. doi: 10.1136/bmjonc-2023-000184. eCollection 2024.
4
Microsatellite Instability in Urine: Breakthrough Method for Bladder Cancer Identification.尿液中的微卫星不稳定性：膀胱癌识别的突破性方法。
Biomedicines. 2024 Nov 28;12(12):2726. doi: 10.3390/biomedicines12122726.
5
Artificial intelligence algorithms enhance urine cytology reporting confidence in postoperative follow-up for upper urinary tract urothelial carcinoma.人工智能算法提高了上尿路尿路上皮癌术后随访中尿液细胞学报告的可信度。
Int Urol Nephrol. 2025 Mar;57(3):801-808. doi: 10.1007/s11255-024-04270-8. Epub 2024 Nov 7.
6
Metabolomic Signatures of Treatment Response in Bladder Cancer.膀胱癌治疗反应的代谢组学特征。
Int J Mol Sci. 2023 Dec 16;24(24):17543. doi: 10.3390/ijms242417543.
7
Bladder cancer.膀胱癌。
Nat Rev Dis Primers. 2023 Oct 26;9(1):58. doi: 10.1038/s41572-023-00468-9.
8
Urinary Biomarkers and Point-of-Care Urinalysis Devices for Early Diagnosis and Management of Disease: A Review.用于疾病早期诊断和管理的尿液生物标志物及即时检验尿液分析设备：综述
Biomedicines. 2023 Mar 29;11(4):1051. doi: 10.3390/biomedicines11041051.
9
Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges.靶向c-Met治疗泌尿系统肿瘤：现状与挑战
Front Oncol. 2023 Mar 7;13:1071030. doi: 10.3389/fonc.2023.1071030. eCollection 2023.
10
Recent Advances in Biosensor Technologies for Point-of-Care Urinalysis.即时尿液分析用生物传感器技术的最新进展。
Biosensors (Basel). 2022 Nov 15;12(11):1020. doi: 10.3390/bios12111020.
本文引用的文献
1
Influencing Factors on the Oncuria™ Urinalysis Assay: An Experimental Model.Oncuria™尿液分析检测的影响因素：一种实验模型
Diagnostics (Basel). 2021 Jun 3;11(6):1023. doi: 10.3390/diagnostics11061023.
2
Urinary Cell-Free DNA in Bladder Cancer Detection.膀胱癌检测中的尿液游离DNA
Diagnostics (Basel). 2021 Feb 14;11(2):306. doi: 10.3390/diagnostics11020306.
3
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.利用游离 DNA 中的甲基化特征进行敏感且特异的多癌种检测和定位。
Ann Oncol. 2020 Jun;31(6):745-759. doi: 10.1016/j.annonc.2020.02.011. Epub 2020 Mar 30.
4
The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence.基于尿液中膀胱癌细胞的 DNA 甲基化鉴定的膀胱 epiCheck 测试作为一种非侵入性工具：已发表证据的综述。
Int J Mol Sci. 2020 Sep 8;21(18):6542. doi: 10.3390/ijms21186542.
5
Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.尿液 DNA 甲基化检测可实现膀胱癌的早期检测和复发监测。
J Clin Invest. 2020 Dec 1;130(12):6278-6289. doi: 10.1172/JCI139597.
6
Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer.尿路上皮膀胱癌中游离DNA热点突变分析的临床意义
Front Oncol. 2020 May 19;10:755. doi: 10.3389/fonc.2020.00755. eCollection 2020.
7
Comparative Analysis of Urine Fractions for Optimal Bladder Cancer Detection Using DNA Methylation Markers.使用DNA甲基化标记物对尿液成分进行比较分析以实现膀胱癌的最佳检测
Cancers (Basel). 2020 Apr 2;12(4):859. doi: 10.3390/cancers12040859.
8
Epidemiology of Bladder Cancer.膀胱癌流行病学
Med Sci (Basel). 2020 Mar 13;8(1):15. doi: 10.3390/medsci8010015.
9
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.膀胱癌临床实践指南（第 3 版）. 2020 年 NCCN 版
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011.
10
Impact of mutations in DNA methylation modification genes on genome-wide methylation landscapes and downstream gene activations in pan-cancer.泛癌中 DNA 甲基化修饰基因突变对全基因组甲基化景观和下游基因激活的影响。
BMC Med Genomics. 2020 Feb 24;13(Suppl 3):27. doi: 10.1186/s12920-020-0659-4.
Zotero 插件